MicroPort MedBot (Group) Co., Ltd. (2252.HK) is a top-tier surgical robot company in China. It’s IPO price was set at HKD 43.2 with 500 share per lot. Its IPO was oversubscribed by 163x. On it’s debut November 2, 2021, the share closed at HKD 45.8 which provide 6..02% return and HKD 1,300 profit per lot. On November 12, 2021, the share closed at HKD 61.7, which provide 42.8% return.

Surgical Robot Market Overview

The PRC surgical robot market is expected to expand from US$0.4 billion in 2020 to US$3.8 billion in 2026, representing a CAGR of 44.3%, while the global market is expected to expand from US$8.3 billion in 2020 to US$33.6 billion in 2026, representing a CAGR of 26.2%.

More Detail About Shanghai MicroPort MedBot (Group) Co., Ltd. (2252.HK)

According to its IPO prospect, the company is a pre-revenue innovative medical device company. Target end-customers are hospitals. The company expect to derive revenue from three sources: systems (i.e., the robots themselves), disposables (e.g., forceps, scissors and sterile drapes) and services (e.g., maintenance and other after-
sale services).

Loss from operations for the year ended December 31 increased from RMB 69,270,000 in 2019 to RMB 158,428,000 in 2020. Loss from operations for the six months ended June 30 increased from RMB 48,763,000 in 2020 to RMB 231,412,000 in 2021.

Conclusion

Investor should aware that MicroPort MedBot (Group) Co., Ltd. (2252.HK) don’t make any revenue yet. There still be a long way for the company to fully commercialize its product and become profitable.

Investment Disclaimers